A pilot dose finding study of MUC1 vaccine in conjunction with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) or Hiltonol in patients with recurrent and/or advanced prostate cancer.
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Prostate cancer vaccine (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.
- 30 Apr 2015 Planned End Date changed from 1 Jul 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 25 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.